Phase classification • Trial completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
|
HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + PGR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)